ArticleFrontiers in pharmacology2025

Nonclinical evaluation of HS630, a proposed biosimilar of trastuzumab emtansine: affinity, pharmacokinetics, and immunogenicity.

Hui Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.